OncoResponse is developing monoclonal antibodies that target immunosuppressive myeloid cells in the tumor microenvironment, utilizing immune responses from patients who have achieved exceptional outcomes with checkpoint inhibitor therapies. This approach aims to convert cold tumors into hot tumors, enhancing immune activity against cancer.
Funding
$124M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many tumors evade the immune system by creating an immunosuppressive microenvironment, rendering checkpoint inhibitor therapies ineffective. These "cold" tumors lack the immune cell infiltration necessary for a robust anti-cancer response.
Solution
OncoResponse is developing a pipeline of monoclonal antibodies designed to reprogram the tumor microenvironment (TME) and enhance anti-tumor immunity. The company's approach leverages insights from "elite responders"—cancer patients who exhibit exceptional responses to checkpoint inhibitors—to identify and target immunosuppressive myeloid cells within the TME. By blocking the activity of these cells, OncoResponse aims to convert immunologically "cold" tumors into "hot" tumors, making them more susceptible to immune-mediated destruction. This strategy seeks to expand the applicability and effectiveness of cancer immunotherapy.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer immunotherapies.
Features
- Monoclonal antibodies targeting specific immunosuppressive myeloid cell populations in the TME
- Discovery platform based on the analysis of immune responses from elite cancer responders
- Preclinical pipeline focused on immunomodulatory antibodies that relieve TME immunosuppression
- Technology designed to convert immunologically "cold" tumors into "hot" tumors
- Antibodies intended to augment immune activity within the tumor microenvironment